Abstract
7000 Background: This phase III study was designed to compare the combination paclitaxel - gemcitabine (PG) versus carboplatin - gemcitabine (CG) in patients with advanced inoperable NSCLC. Methods: Chemotherapy - naïve patients with performance status (PS) of 0 or 1 were randomized to gemcitabine 1gm/m2 on days 1 and 8 plus either paclitaxel 200mg/m2 on day 1 (arm A) or Carboplatin at an area under the concentration - time curve of 6 on day 1 (arm B) every 3 weeks. Primary endpoint was overall survival (OS). Secondary endpoints included objective response (OR), time to progression (TTP) and toxicity. For a two-sided test at the 5% level of significance and power of 80%, the number of patients required to detect a 10% difference in survival rate was 417. Results: A total of 512 patients were enrolled and 445 evaluable (arm A, 222; arm B, 223) were analyzed. All characteristics were well balanced. As shown in the table below with a median follow-up time 23 mos (0.1 - 48.16) there was no difference in the OS, one-year survival, OR and TTP. However, statistically significant differences were seen in toxicity. Conclusions: The two regimens are equally active. Myelotoxicity is worse in the CG group whereas alopecia, myalgia and neurotoxicity worse in the PG group. No significant financial relationships to disclose.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.